IONS Quote, Financials, Valuation and Earnings

Cogent Biosciences, Inc. has a net margin of -82.06% compared to Ionis Pharmaceuticals, Inc.'s net margin of --. Ionis Pharmaceuticals, Inc.'s return on equity of -43.01% beat Cogent Biosciences, Inc.'s return on equity of -117.99%.

Ionis Pharmaceuticals, Inc. has a consensus price target of $90.67, signalling upside risk potential of 4.82%. On the other hand Cogent Biosciences, Inc. has an analysts' consensus of $50.75 which suggests that it could grow by 36.87%. Given that Cogent Biosciences, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Cogent Biosciences, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

Ionis Pharmaceuticals, Inc. has a beta of 0.291, which suggesting that the stock is 70.94% less volatile than S&P 500. In comparison Cogent Biosciences, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.923%.

Ionis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cogent Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Cogent Biosciences, Inc. pays out -- of its earnings as a dividend.

Ionis Pharmaceuticals, Inc. quarterly revenues are $156.7M, which are larger than Cogent Biosciences, Inc. quarterly revenues of --. Ionis Pharmaceuticals, Inc.'s net income of -$128.6M is lower than Cogent Biosciences, Inc.'s net income of -$80.9M. Notably, Ionis Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Cogent Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals, Inc. is 14.73x versus 55.99x for Cogent Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -82.06% compared to Ionis Pharmaceuticals, Inc.'s net margin of 20.83%. Ionis Pharmaceuticals, Inc.'s return on equity of -43.01% beat Johnson & Johnson's return on equity of 33.27%.

Ionis Pharmaceuticals, Inc. has a consensus price target of $90.67, signalling upside risk potential of 4.82%. On the other hand Johnson & Johnson has an analysts' consensus of $230.63 which suggests that it could fall by -3.9%. Given that Ionis Pharmaceuticals, Inc. has higher upside potential than Johnson & Johnson, analysts believe Ionis Pharmaceuticals, Inc. is more attractive than Johnson & Johnson.

Ionis Pharmaceuticals, Inc. has a beta of 0.291, which suggesting that the stock is 70.94% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.350, suggesting its less volatile than the S&P 500 by 64.977%.

Ionis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.14% to investors and pays a quarterly dividend of $1.30 per share. Ionis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ionis Pharmaceuticals, Inc. quarterly revenues are $156.7M, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Ionis Pharmaceuticals, Inc.'s net income of -$128.6M is lower than Johnson & Johnson's net income of $5.1B. Notably, Ionis Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 21.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals, Inc. is 14.73x versus 6.19x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -82.06% compared to Ionis Pharmaceuticals, Inc.'s net margin of 34.4%. Ionis Pharmaceuticals, Inc.'s return on equity of -43.01% beat Eli Lilly & Co.'s return on equity of 106.26%.

Ionis Pharmaceuticals, Inc. has a consensus price target of $90.67, signalling upside risk potential of 4.82%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,183.22 which suggests that it could grow by 11.82%. Given that Eli Lilly & Co. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Eli Lilly & Co. is more attractive than Ionis Pharmaceuticals, Inc..

Ionis Pharmaceuticals, Inc. has a beta of 0.291, which suggesting that the stock is 70.94% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

Ionis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.57% to investors and pays a quarterly dividend of $1.50 per share. Ionis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ionis Pharmaceuticals, Inc. quarterly revenues are $156.7M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Ionis Pharmaceuticals, Inc.'s net income of -$128.6M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Ionis Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 46.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals, Inc. is 14.73x versus 14.60x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -82.06% compared to Ionis Pharmaceuticals, Inc.'s net margin of 18.06%. Ionis Pharmaceuticals, Inc.'s return on equity of -43.01% beat Merck & Co., Inc.'s return on equity of 39.63%.

Ionis Pharmaceuticals, Inc. has a consensus price target of $90.67, signalling upside risk potential of 4.82%. On the other hand Merck & Co., Inc. has an analysts' consensus of $121.27 which suggests that it could fall by -0.54%. Given that Ionis Pharmaceuticals, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Ionis Pharmaceuticals, Inc. is more attractive than Merck & Co., Inc..

Ionis Pharmaceuticals, Inc. has a beta of 0.291, which suggesting that the stock is 70.94% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.280, suggesting its less volatile than the S&P 500 by 72.042%.

Ionis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.69% to investors and pays a quarterly dividend of $0.85 per share. Ionis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ionis Pharmaceuticals, Inc. quarterly revenues are $156.7M, which are smaller than Merck & Co., Inc. quarterly revenues of $16.4B. Ionis Pharmaceuticals, Inc.'s net income of -$128.6M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Ionis Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 16.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals, Inc. is 14.73x versus 4.70x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.